Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. Blood Adv 2019 07 09;3(13):1926-1929

Date

06/28/2019

Pubmed ID

31243002

Pubmed Central ID

PMC6616259

DOI

10.1182/bloodadvances.2018025726

Author List

Keating AK, Gossai N, Phillips CL, Maloney K, Campbell K, Doan A, Bhojwani D, Burke MJ, Verneris MR

Author

Michael James Burke MD Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Antibodies, Bispecific
Antineoplastic Agents
Child
Child, Preschool
Female
Humans
Incidence
Infant
Infant, Newborn
Male
Neoplasm, Residual
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Stem Cell Transplantation
Treatment Outcome
Young Adult
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a